锐客网

  1. 首页 > 科技 > >

{调取该文章的TAG关键词}|Capital Flooding Chinese AI Pharma Firms in Pre-B Round Funding

During the digital transformation of China's healthcare industry, a large number of institutional investors have jumped on the bandwagon of early-stage funding into pharmaceutical startups in the past two years. 
New technologies, including artificial intelligence and big data, continue to emerge, reshaping pharmaceutical research and development. If institutional investors want to seize future opportunities in the field, they need to invest in such startups as early as possible. For another thing, in the past two years, the secondary market has continuously undergone institutional innovations, which has opened a financing channel for unprofitable biomedical technology companies. It has altered the investment flow of the primary market to a certain extent, reducing the late-stage investment opportunities and heating up the early-stage investments.
【{调取该文章的TAG关键词}|Capital Flooding Chinese AI Pharma Firms in Pre-B Round Funding】In the innovation generated by the digital transformation of medical care, big data's application in the pharmaceutical field has helped solve the problems of high costs and long process during the research and development of new drugs by pharmaceutical companies, and Al Pharmaceutical has become a popular target of capital.
In China, AI pharmaceutical has enormous space for development.
According to the “2021-2026 AI Pharmaceutical Industry Venture Capital Dynamics and Financing Strategy Guidance Report” released by Newsijie Industry Research Center, there are about 245 AI pharmaceutical companies around the world, and most AI pharmaceutical companies are concentrated in developed countries, in which the United States ranks first with a share of 55%, followed by Britain with 15% and Canada with about 7%. China has fewer companies in the AI pharmaceutical sector at present, accounting for about 3% of the global market.
A few days ago, the Sixth China Great Health Industry Upgrading Summit released the “2021 China AI/ Computing Pharmaceutical Industry Report: Drug Discovery”. The report shows that AI/computing technology is in the verification period from concept to scale. The clinical research of a drug is an important milestone in the process of drug research and development, which means the drug molecule has been initially proved its vitro activity and safety through layers of screening and experiments. It has also achieved relatively good results in animal trials, and then entered clinical trials, the success rate has been greatly improved. After passing the clinical trial, a drug can be sold on the market.
So far, more than 30 candidate compounds involved in AI/computing technology in the world have entered the IND (clinical trial approval) stage, in which China has disclosed two. Although China’s AI pharmaceutical business accounts for a small proportion of the whole world, China market is not dull as the rest of the world is gaining momentum. 
The report also shows that the investment enthusiasm of Chinese AI/computing pharmaceutical companies has been mounting. It has reached a peak in the past two years, with most financing concentrated before series B funding.
Investment and financing in AI/computing pharmaceutical field in China (2015-2021)  (The data comes from “2021 China AI / Computing Pharmaceutical Industry Report: Drug Discovery”)
It is worth noting that in the field of AI Pharmaceuticals, a more segmented field has been particularly hot. It is the application of real-world data in Al pharmaceuticals.
“The difficulty of new drug research and development is the high cost. Only 20% to 30% of new drug research and development can really pass the test from phase I to phase III. Most of the costs of drug companies are in the early exploration and attempt, through mining the real-world data of tumors, to find more accurate patients for the early research and development of new drugs. That is to say, biomarker will pay attention to the screening of the target population of new drug research and development.” Zhao Ping, senior vice president of the Pharmaceutical Enterprise Cooperation Division of OrigiMed, said.

推荐阅读


上一篇：像素|最前线｜荣耀发布7.09英寸超大屏幕手机，售价2399元起

下一篇：遥控器|浩瀚X2手机稳定器测评！升级更明显、视频更稳定，出门炸街神器